Dengue vaccine likely by 2019-end, says Panacea Biotec - ( via NewsPoints Desk)

  • Panacea Biotec said it has secured permission to conduct Phase I/II trials for its live attenuated tetravalent dengue vaccine in India, and the product could be available there as of the end of 2019, reported

  • A company spokesperson said Panacea Biotec will start clinical trials by early 2018.

  • "As dengue is a big challenge for India and a vaccine is direly required, we have given a go-ahead for trials for dengue vaccine by TDB [Technology Development Board] and Panacea Biotec," stated G.N. Singh of the Drug Controller General of India (DCGI).

  • "We are facilitating the trials in a speedy manner. As a regulator, we are ensuring that the vaccine is effective and safe for the people," Singh added.

  • The experimental vaccine is a single-dose injection and has been found to stimulate a strong immune response against all four types of dengue viruses in all age groups, according to results from clinical trials conducted by the US National Institutes of Health.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.